NEW YORK, Aug. 25 /PRNewswire-FirstCall/ -- NeoStem Inc. (NYSE Amex: NBS) which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that the Company's CEO, Robin Smith, M.D. MBA, has been invited to participate in the 2009 World Stem Cell Summit to be held in Baltimore, Maryland, next month.
Dr. Smith will participate on the panel, "Cord Blood and Cell Banking: Answers for Patients, Researchers and Industry," scheduled for Wednesday, September 23rd, from 4:00 to 5:15 PM. She will be one of 100 presenting experts, attendees from 36 countries and representatives from more than 151 sponsors and supporting organizations and media partners at this preeminent international networking event.
The 2009 Summit will take place September 21-23 at the Baltimore Convention Center. It is presented by the Genetics Policy Institute and hosted by Johns Hopkins University, the University System of Maryland, and the State of Maryland. The comprehensive, multi-track program covers advanced science, commercial perspectives, disease progress reports and in-depth reviews of policy, law, ethics, regulatory issues and global economic development.
Dr. Smith stated, "I am very pleased to take part in this international Summit, as it brings together leading researchers, scientists, industry leaders, funders, policy makers, advocates, educators and regulators who are charting the future of regenerative medicine. This field has gained enormous vitality in just the past couple of years. I am proud that NeoStem Inc. is on the forward edge of new therapies and technologies whose potential to save and change many lives is expanding exponentially."
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China. For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: email@example.com
|SOURCE NeoStem, Inc.|
Copyright©2009 PR Newswire.
All rights reserved